Sarepta Therapeutics, Inc. (SRPT) Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Sarepta Therapeutics, Inc. NASDAQ:SRPT Healthcare · Biotechnology
Mkt Cap $1.97B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics announced senior management participation in two investor conferences on Nov. 9, 2026: the 8th Annual Wolfe Research Healthcare Conference in New York and the Guggenheim Securities 3rd Annual Healthcare Innovation Conference in Boston.
The Guggenheim fireside chat at 3 p.m. ET will be webcast live on Sarepta's investor relations site and archived for 90 days.
The release contains no new financial or pipeline information.
• 6d ago AI analysis › Press Release
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
Sarepta Therapeutics will report third quarter 2026 financial results after the Nasdaq close on Thursday, Nov. 5, 2026.
The company will host a conference call at 4:30 p.m. ET the same day, with a live webcast and one-year replay available on its investor relations site.
No results or guidance are included in this notice; it is a scheduling announcement ahead of the earnings date.
• 10d ago AI analysis › Press Release
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Sarepta presented new preclinical data at the Oligonucleotide Therapeutics Society meeting showing its DM1 siRNA candidate SRP-1003 reduces pathogenic DMPK RNA in the nucleus, achieving up to approximately 80% knockdown in both nuclear and cytoplasmic compartments in a dose-dependent manner.
Nuclear target engagement was confirmed by three independent methods (RNA FISH, compartment-fractionated ddPCR, and RNAscope), and MBNL-dependent mis-splicing correction provided functional evidence of nuclear activity.
SRP-1003 showed sustained exposure across multiple muscle groups for up to 16 weeks after a single IV dose in preclinical models. The company continues its first-in-human Phase 1/2 study (SRP-1003-101) and expects to share results later this year.
• 18d ago AI analysis › Press Release
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics granted 211,070 restricted stock units as inducement awards to 37 employees hired in the third quarter of 2026.
The awards were made under the company's 2024 Employment Commencement Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with annual vesting over four years.
This is routine compensation housekeeping with no material financial or pipeline impact.
• 1mo ago AI analysis › Press Release ⚠ 3
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
Sarepta presented new WMS 2026 data showing ELEVIDYS delivered durable, clinically meaningful functional benefit over two years in ambulatory Duchenne patients treated at ages 8-12 versus a well-matched external control.
Treated patients (n=25) outperformed external controls (n=99) on NSAA (+3.32 points, P=0.0022) and timed function tests, with safety consistent with the known profile and no new signals.
A separate analysis in children treated at ages 2 to under 3 showed robust micro-dystrophin expression at 12 weeks, expanding the evidence base toward younger ages, though use under age 4 remains investigational.
• 1mo ago AI analysis › Press Release
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Sarepta will present new Duchenne muscular dystrophy data at the 31st Annual Congress of the World Muscle Society, Sept. 29 - Oct. 3, in Hiroshima, Japan.
Presentations include a late-breaking poster on ELEVIDYS efficacy and safety in older ambulatory patients aged 8-12 at treatment, plus EMBARK three-year outcomes and pooled Phase 1-3 safety analyses.
Data will be posted to Sarepta's investor relations site after presentation; the release is routine scientific communications with no new regulatory or financial disclosures.
• 1mo ago AI analysis › Press Release
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
Sarepta will present seven posters at the 27th Annual Neuromuscular Study Group Scientific Meeting, Sept. 25-27, 2026, in San Antonio, Texas.
The highlight is the first results from the Phase 4 ENDURE study, a real-world observational study of ELEVIDYS in Duchenne muscular dystrophy clinical care, including safety with sirolimus prophylactic immunosuppression.
Interim Phase 1/2 safety and exposure data for pipeline siRNA candidates SRP-1003 (DM1) and SRP-1001 (FSHD1) will also be shown; the release is a routine data-preview announcement with no new financial or regulatory disclosures.
• 1mo ago AI analysis › Press Release
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
Sarepta Therapeutics announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year — 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with the condition.
Now in its ninth year, the program has awarded more than 150 scholarships total, with each student receiving up to $5,000 toward postsecondary education. Recipients are selected by an independent committee of Duchenne community members on a de-identified basis, with no visibility into whether a candidate receives a Sarepta therapy.
This is a community/CSR announcement with no bearing on Sarepta's financials, pipeline progress, or regulatory outlook; treat as non-market-moving.
• 1mo ago AI analysis › Press Release
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Sarepta Therapeutics announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 14.
The presentation is scheduled for 8:30 a.m. ET and will be webcast live on the company's investor relations website.
A replay of the event will be archived on the website for 90 days following the presentation.
• 2mo ago AI analysis › Press Release ● Major ⚠ 3
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta reported Q2 2026 total revenue of $401.3 million, down 34% year-over-year, while achieving both GAAP and non-GAAP operating profitability of $13.3 million and $86.5 million respectively. The revenue decline primarily reflects lower ELEVIDYS sales following a label update limiting use to ambulatory patients and the absence of a prior-year collaboration milestone payment from Roche.
Michael Severino, MD, has assumed the role of CEO effective July 28, 2026, succeeding Doug Ingram who retired but will advise through the end of the year. Concurrently, the company narrowed its FY 2026 total net product revenue guidance to $1.2-$1.3 billion, consistent with the lower end of prior expectations, and recorded a $39.0 million litigation contingency charge.
Pipeline advancements include FDA acceptance of supplemental NDAs for traditional approval of AMONDYS 45 and VYONDYS 53. Management confirmed that data readouts for DM1 and FSHD programs remain on track for the second half of 2026, and dosing has begun in the Phase 1 Huntington's disease study of SRP-1005.
• 2mo ago AI analysis › Press Release
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics granted equity inducement awards to new CEO Dr. Michael Severino, consisting of options to purchase 2.22 million shares and 756,104 restricted stock units.
The options carry an exercise price of $17.74 per share, representing a 15% premium to the closing price on the grant date of July 28, 2026.
Vesting for both awards occurs over four years, with options vesting monthly after the first year and RSUs vesting annually.
• 3mo ago AI analysis › Press Release ● Major ⚠ 1
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
Sarepta Therapeutics appointed Michael Severino, M.D. as its new chief executive officer, effective July 28, 2026, succeeding retiring CEO Doug Ingram.
Severino joins the company from Tessera Therapeutics and previously served as Vice Chairman and President at AbbVie, bringing over 25 years of experience in genetics and precision medicine.
Ingram will remain with Sarepta in an advisory capacity through the end of 2026 to facilitate a smooth leadership transition, while Severino also joins the Board of Directors.
• 3mo ago AI analysis › Press Release
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
Sarepta Therapeutics will report its second quarter 2026 financial results after the Nasdaq market closes on Wednesday, August 5, 2026.
The company will host a conference call at 4:30 p.m. E.T. to discuss the results, which will be webcast live on the investor relations section of its website.
A replay of the call will be archived on the website for one year following the event.
• 3mo ago AI analysis › Press Release
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics granted inducement equity awards to 30 individuals hired during the second quarter of 2026.
The awards consist of an aggregate of 151,305 restricted stock units, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest annually over four years, with one-fourth vesting on each anniversary of the grant date, subject to continued employment.
• 4mo ago AI analysis › Press Release ⚠ 2
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
Sarepta announced that the FDA accepted supplemental NDAs for AMONDYS 45 and VYONDYS 53 for filing, assigning a PDUFA target action date of February 28, 2027.
The applications seek to convert accelerated approvals to traditional approvals, supported by the Phase 3 ESSENCE study and real-world evidence, despite the confirmatory trial missing its primary endpoint.
Management noted that over 1,800 patients worldwide have been treated across the exon-skipping portfolio, with observed preservation of muscle function and slowed disease progression.
• 4mo ago AI analysis › Press Release
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
Sarepta Therapeutics announced that senior management will participate in two investor conferences in June.
The company will hold a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 and investor meetings at the Oppenheimer CNS and Neuro-Muscular Summit on June 10.
The Goldman Sachs presentation will be webcast live and archived on Sarepta’s investor relations website for 90 days.
• 5mo ago AI analysis › Press Release
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
businesswire.com • 5mo ago Press Release ● Major
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
businesswire.com • 5mo ago Press Release
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
Sarepta Therapeutics announced that it will report its first quarter 2026 financial results after the market closes on May 6, 2026.
The company will host a conference call at 4:30 p.m. E.T. to discuss the results, with a live webcast available on its investor relations website.
A replay of the call will be archived on the website for one year following the event.
• 6mo ago AI analysis › Press Release ● Major
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • 7mo ago 
